CD274 and cancer: Although immune checkpoint blockade has achieved clinical success in cancer treatment and several drugs have been approved by FDA to treat cancers, a great proportion of patients could not exhibit sustained clinical response to the anti-PD-1/PD-L1 immunotherapy (117).